BofA Securities expects ALI HEALTH's FY2026 revenue to meet expectations but has lowered its adjusted net profit forecast due to increased investments in AI and innovative drug sales. As a result, the target price has been reduced from $6.56 to $6, while maintaining a Buy rating.
